Mizuho Securities Reiterates a Buy Rating on Avrobio (AVRO)

In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on Avrobio (AVROResearch Report), with a price target of $28.00. The company’s shares closed last Tuesday at $8.88.

According to TipRanks.com, Yang has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -6.7% and a 32.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Xeris Pharmaceuticals, and Magenta Therapeutics.

Currently, the analyst consensus on Avrobio is a Moderate Buy with an average price target of $20.75, an 115.7% upside from current levels. In a report released today, Wells Fargo also maintained a Buy rating on the stock with a $36.00 price target.

See today’s analyst top recommended stocks >>

Avrobio’s market cap is currently $395.9M and has a P/E ratio of -3.50. The company has a Price to Book ratio of 1.92.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. These gene therapies, on which the company was founded, were developed by Dr. Jeffrey Medin and Dr. Christopher Paige at the University Health Network. AvroBio launched in 2015, is headed by Co-Founder, President and CEO Geoff Mackay, and is headquartered in Cambridge, MA.